Takeda, Astellas, Eisai Look Outside For Cost-Cutting R&D Help
This article was originally published in PharmAsia News
Japan's biggest drug makers are looking beyond their companies and their industry to find ways to cut drug-development costs
You may also be interested in...
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.